HURA stock forecast, quote, news & analysis
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies... Show more
TuHURA Biosciences (HURA) Stock Analysis: IFx-2.0 Data Readouts Put a Clinical-Stage Biotech Back in Focus
Key Takeaways
- TuHURA Biosciences (HURA) has traded roughly flat over the trailing month, ending near $2.11 after a sharp late-October rally.
- Preliminary data from its open-label IFx-2.0 study showed confirmed tumor responses in the first patients with metastatic Merkel cell carcinoma.
- The U.S. Patent and Trademark Office issued a new patent broadening coverage for the company's VISTA inhibitor, TBS-2025.
- The company remains pre-revenue and clinical-stage, with an analyst consensus rating of "Buy" and an average 12-month price target near $8.04.
- HURA is a high-volatility micro-cap, with a 52-week trading range of roughly $0.41 to $3.43.
- For deeper data on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Investors seeking systematic strategies can also explore Trending AI Robots.
Current Market Snapshot
TuHURA Biosciences (HURA) closed the most recent session near $2.11, up about 3.4% on the day. Over the trailing 30 days the stock has been essentially flat, though that headline obscures significant intra-period volatility: shares slid below $1.80 in mid-October before rebounding sharply following a clinical data update and new patent issuance. With a market capitalization of roughly $134 million and no product revenue to date, HURA trades more like a binary biotech asset than a steady-growth equity, and its weekly price swings have been substantially wider than the broader market.
Sentiment is concentrated around a small group of covering analysts, who currently hold a consensus "Buy" rating with a 12-month average target near $8.04. The wide gap between the current price and that target reflects both the early-stage nature of the pipeline and the high uncertainty embedded in clinical development.
TuHURA Biosciences (HURA) Business Overview and Competitive Position
TuHURA Biosciences is a clinical-stage immuno-oncology company headquartered in Tampa, Florida, focused on overcoming primary and acquired resistance to cancer immunotherapies. Its lead candidate, IFx-2.0, is an innate immune agonist designed to make tumor cells resemble bacteria so the body's own immune system attacks them, and it is being studied as an adjunctive therapy to checkpoint inhibitors such as Keytruda.
The pipeline also includes a Delta receptor technology platform aimed at developing tumor microenvironment modulators, including bi-functional and bi-specific antibody-drug conjugates that target myeloid-derived suppressor cells, as well as the mRNA-based candidate IFx-3.0 for blood-related cancers and the VISTA inhibitor TBS-2025. Investors follow the stock primarily for clinical readouts and regulatory milestones, since the company has yet to generate product revenue.
Recent Developments Driving HURA
The most significant recent catalyst was the initial data from TuHURA's open-label study of IFx-2.0 in the first-line treatment of patients with deep-seated metastatic Merkel cell carcinoma. The company reported that the first three treated patients achieved confirmed objective responses sustained through week 24, with no serious adverse events reported across the four patients treated so far. The 9-to-12-patient study is intended to inform feasibility, safety, and potential discussions with the FDA.
Separately, the U.S. Patent and Trademark Office issued a new patent that broadens coverage for TBS-2025, the company's VISTA-inhibiting antibody, extending it to include bispecific and multi-specific antibodies across classes of human antibodies. These announcements contributed to a pronounced volume spike and price rebound in late October, though the stock has not yet sustained a breakout beyond its recent range.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of top-performing artificial intelligence trading bots from a platform that offers hundreds of bots trading thousands of tickers. Because only the most relevant and best-performing bots appear in this section, the list serves as a way for traders to discover systematic strategies without sifting through the entire catalog. The bots vary in strategy, timeframe, and performance metrics, so investors can review criteria such as win rate and return history before committing to a particular approach. For those interested in data-driven trading ideas, Trending AI Robots offers a starting point for further exploration.
2026 Outlook and What Investors Should Watch
Looking ahead, the key events for HURA center on clinical execution and data catalysts. Investors will monitor further results from the IFx-2.0 Merkel cell carcinoma study, including durability of responses and safety across additional patients, as well as any progress toward FDA discussions and the planned Phase 3 registration trial. Additional milestones could include development updates on the Delta receptor antibody-drug conjugate platform, IFx-3.0, and the VISTA inhibitor TBS-2025.
On the financial side, the company's quarterly results, with an estimated earnings report in mid-November 2026, will be watched for cash runway, operating-expense trends, and any financing activity, given that TuHURA remains pre-revenue. As a clinical-stage micro-cap, HURA is also sensitive to broader biotechnology financing conditions and risk sentiment. These factors, rather than near-term revenue, will likely shape the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HURA's Stochastic Oscillator is sitting in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HURA's RSI Oscillator exited the oversold zone, 33 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where HURA advanced for three days, in 179 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HURA as a result. In 88 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for HURA turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 41 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
HURA moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for HURA moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
HURA broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HURA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.701) is normal, around the industry mean (3.498). P/E Ratio (-3.019) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. HURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology